Breakthroughs in understanding and treating eosinophilic gastrointestinal diseases presented at the CEGIR/TIGERs Symposium at the 2022 American Academy of Allergy, Asthma & Immunology Meeting

Mirna Chehade*, Benjamin L. Wright, Dan Atkins, Seema S. Aceves, Steven J. Ackerman, Amal H. Assa'ad, Maureen Bauer, Margaret H. Collins, Scott P. Commins, Carla M. Davis, Evan S. Dellon, Bethan Doerfler, Gerald J. Gleich, Sandeep K. Gupta, David A. Hill, Elizabeth T. Jensen, David Katzka, Kara Kliewer, Ellyn Kodroff, Leah C. KottyanShay Kyle, Amanda B. Muir, Robert D. Pesek, Kathryn Peterson, Wayne G. Shreffler, Jonathan M. Spergel, Mary Jo Strobel, Joshua Wechsler, Nives Zimmermann, Glenn T. Furuta, Marc E. Rothenberg

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations

Abstract

The Consortium of Eosinophilic Gastrointestinal Diseases and The International Gastrointestinal Eosinophil Researchers organized a day-long symposium at the 2022 Annual Meeting of the American Academy of Allergy, Asthma & Immunology. The symposium featured a review of recent discoveries in the basic biology and pathogenesis of eosinophilic gastrointestinal diseases (EGIDs) in addition to advances in our understanding of the clinical features of EGIDs. Diagnostic and management approaches were reviewed and debated, and clinical trials of emerging therapies were highlighted. Herein, we briefly summarize the breakthrough discoveries in EGIDs.

Original languageEnglish (US)
Pages (from-to)1382-1393
Number of pages12
JournalJournal of Allergy and Clinical Immunology
Volume152
Issue number6
DOIs
StatePublished - Dec 2023

Funding

We also thank the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) (U54AI117804), which is part of the Rare Disease Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), NCATS, and funded through collaboration between NIAID, NIDDK, and NCATS. CEGIR is also supported by patient advocacy groups including American Partnership for Eosinophilic Disorders (APFED), Campaign Urging Research for Eosinophilic Diseases (CURED), and Eosinophilic Family Coalition (EFC). As a member of the RDCRN, CEGIR is also supported by its Data Management and Coordinating Center (DMCC) (U2CTR002818). Funding support for the DMCC is provided by the National Center for Advancing Translational Sciences (NCATS) and the National Institute of Neurological Disorders and Stroke (NINDS).

Keywords

  • Eosinophilic esophagitis
  • eosinophil
  • eosinophilic gastritis
  • food allergy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint

Dive into the research topics of 'Breakthroughs in understanding and treating eosinophilic gastrointestinal diseases presented at the CEGIR/TIGERs Symposium at the 2022 American Academy of Allergy, Asthma & Immunology Meeting'. Together they form a unique fingerprint.

Cite this